Adial Pharmaceuticals Future Growth

Future criteria checks 0/6

Adial Pharmaceuticals is forecast to grow earnings and revenue by 3.7% and 89% per annum respectively while EPS is expected to grow by 48.3% per annum.

Key information

3.7%

Earnings growth rate

48.3%

EPS growth rate

Pharmaceuticals earnings growth	23.6%
Revenue growth rate	89.0%
Future return on equity	n/a
Analyst coverage	Low
Last updated	17 Oct 2024

Recent future growth updates

Recent updates

Adial Clinical Trial: A Fluff Or A Win?

Aug 22

Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01

Aug 16

Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst

Jun 21

Adial Pharmaceuticals shares +5% on receiving third patent for opioid use disorder candidate

Jan 11

Adial Pharmaceuticals inks stock purchase agreement with Keystone Capital

Nov 25

Earnings and Revenue Growth Forecasts

NasdaqCM:ADIL - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-17	N/A	N/A	2
12/31/2025	N/A	-9	N/A	N/A	3
12/31/2024	N/A	-13	N/A	N/A	3
6/30/2024	N/A	-12	-6	-6	N/A
3/31/2024	N/A	-11	-6	-6	N/A
12/31/2023	N/A	-7	-7	-7	N/A
9/30/2023	N/A	-8	-7	-7	N/A
6/30/2023	N/A	-9	-9	-9	N/A
3/31/2023	N/A	-10	-11	-11	N/A
12/31/2022	N/A	-11	-11	-11	N/A
9/30/2022	N/A	-14	-12	-12	N/A
6/30/2022	N/A	-16	-12	-12	N/A
3/31/2022	N/A	-17	-12	-12	N/A
12/31/2021	N/A	-19	-12	-12	N/A
9/30/2021	N/A	-17	-12	-12	N/A
6/30/2021	N/A	-16	-11	-11	N/A
3/31/2021	N/A	-13	-9	-9	N/A
12/31/2020	N/A	-11	-8	-8	N/A
9/30/2020	N/A	-9	-7	-7	N/A
6/30/2020	N/A	-8	-6	-6	N/A
3/31/2020	N/A	-8	-6	-6	N/A
12/31/2019	N/A	-9	-6	-6	N/A
9/30/2019	N/A	-8	-6	-6	N/A
6/30/2019	N/A	-14	-5	-5	N/A
3/31/2019	N/A	-14	-4	-4	N/A
12/31/2018	N/A	-12	-2	-2	N/A
9/30/2018	N/A	-11	-2	-2	N/A
6/30/2018	N/A	-3	-1	-1	N/A
3/31/2018	N/A	-1	N/A	-1	N/A
12/31/2017	N/A	-1	N/A	0	N/A
9/30/2017	N/A	-1	N/A	0	N/A
6/30/2017	N/A	-1	N/A	0	N/A
3/31/2017	N/A	0	N/A	0	N/A
12/31/2016	N/A	0	N/A	0	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ADIL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ADIL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ADIL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ADIL is forecast to have no revenue next year.

High Growth Revenue: ADIL is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ADIL's Return on Equity is forecast to be high in 3 years time

Adial Pharmaceuticals Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 19% to US$21.00

Price target decreased by 17% to US$17.00

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Price target increased to US$10.67

Forecast breakeven pushed back to 2024

Recent updates

Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Genetic Diagnostic for Addiction Treatment

Adial Pharmaceuticals, Inc., Annual General Meeting, Nov 12, 2024

Adial Pharmaceuticals, Inc. Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

New major risk - Financial position

Adial Pharmaceuticals, Inc. Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend Ip Exclusivity on Core Technology to 2044

Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of Ad04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals, Inc. Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $4.28365 million.

Adial Pharmaceuticals, Inc Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Adial Pharmaceuticals, Inc. announced that it has received $0.2875 million in funding

Price target decreased by 19% to US$21.00

New major risk - Share price stability

Price target decreased by 17% to US$17.00

Adial Pharmaceuticals, Inc. Appoints Tony Goodman as Chief Operating Officer

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement

Adial Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

Adial Pharmaceuticals, Inc. announced delayed amended 10-Q filing

Adial Pharmaceuticals, Inc. announced that it has received $4.000001 million in funding

Adial Pharmaceuticals, Inc. announced that it expects to receive $4.000001 million in funding

Adial Pharmaceuticals Receives Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence

Adial Pharmaceuticals, Inc., Annual General Meeting, Nov 02, 2023

Adial Pharmaceuticals, Inc. Announces Board Changes

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Adial Pharmaceuticals, Inc. announced delayed 10-Q filing

Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement and Reduce the Public Float

New major risk - Share price stability

Adial Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Regarding Compliance with Nasdaq Listing Rule 5550(b)(1)

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Adial Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Adial Pharmaceuticals, Inc., Annual General Meeting, Oct 13, 2022

Adial Pharmaceuticals, Inc. Announces Executive Changes

Adial Clinical Trial: A Fluff Or A Win?

Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01

Adial Pharmaceuticals, Inc. Announces Topline Results For Onward Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder

Adial Pharmaceuticals Announces Database Lock for the ONWARD(TM) Phase 3 Clinical Trial

Price target increased to US$10.67

Adial Pharmaceuticals Announces Completion of Last Patient, Last Visit in its ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder

Adial Pharmaceuticals Receives Notice of Allowance on U.S. Patent for the Treatment for Opioid Use Disorder Using AD04

Independent Director recently bought US$67k worth of stock

Adial Pharmaceuticals, Inc. announced that it has received $0.8 million in funding from Bespoke Growth Partners, Inc.

Chairman recently bought US$55k worth of stock

Adial Pharmaceuticals, Inc. Announces Positive Pre-Clinical Data for PNV2 as A Drug Candidate for Triple Negative Breast Cancer

Director William Stilley has joined 3rd company board

Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder

Adial Pharmaceuticals, Inc. Reaches Full Enrollment Target for ONWARD Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder

Adial Pharmaceuticals, Inc. announced that it has received $5.000004 million in funding from Bespoke Growth Partners, Inc., Keystone Capital Partners LLC

Adial Pharmaceuticals Provides Regulatory and Development Update

Adial Pharmaceuticals, Inc. Plans to Enter Genetic Testing Market Following Allowance of U.S. Patent for Genetic Diagnostic Test

Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst

Adial Pharmaceuticals, Inc. announced that it has received $2.100003 million in funding from Keystone Capital Partners LLC, Bespoke Growth Partners, Inc., Rountop Limited Partnership, LLP and another investor

Forecast breakeven pushed back to 2024

Adial Pharmaceuticals Achieves 50% Enrollment in landmark ONWARD™ Phase 3 Trial

Adial Pharmaceuticals, Inc. to File Fast Track Application for Ad04 with the FDA

New 90-day high: US$3.19

Adial Pharmaceuticals, Inc. (NasdaqCM:ADIL) completed the acquisition of Purnovate, LLC from the members of Purnovate.

New 90-day high: US$2.34

Adial Pharmaceuticals shares +5% on receiving third patent for opioid use disorder candidate

Adial Pharmaceuticals, Inc. (NasdaqCM:ADIL) entered into an Equity Purchase Agreement to acquire Purnovate, LLC from the members of Purnovate.

Adial Pharmaceuticals, Inc. Announces Management and Board Changes, Effective December 14, 2020

Adial Pharmaceuticals, Inc. announced that it expects to receive funding from Keystone Capital Partners LLC

Adial Pharmaceuticals inks stock purchase agreement with Keystone Capital

Adial Pharmaceuticals, Inc. Announces That U.S. Food and Drug Administration Issues an Emergency Use Authorization for the Assure/Fastep® Covid-19 Igg/Igm Rapid Test Device

Adial Pharmaceuticals, Inc. Files for Expedited Review of AD04 with the FDA

Adial Pharmaceuticals, Inc. announced that it has received $0.5 million in funding from Bespoke Growth Partners, Inc.

New 90-day low: US$1.21